The key efficacy endpoint was improve from baseline MADRS score. This short-time period review discovered that, compared to intranasal placebo furthermore oral antidepressant, intranasal esketamine in conjunction with an oral antidepressant significantly improved depressive signs or symptoms following 4 months by a mean difference of four points on the MADRS. https://stevep899mcr7.wikibuysell.com/user